Ludovica Di Martino earned her Master’s Degree in pharmaceutical Biotechnology cum Laude at University of Bologna in 2019. She then moved to University of Ghent, Belgium, as a visiting scientist, in Professor Pieter Van Vlierberghe’s laboratory. During this time she had the opportunity to develop interest in analysing gene expression data and epigenetic regulation data and learned related laboratory techniques. She subsequently pursued a PhD program in Immunology and Experimental Oncology at University of Padua, with a project focused on amino acids metabolism in T cell acute lymphoblastic leukaemia (T-ALL). Her research as a doctoral student was focused on the role of Branched Chain Amino Acid Transaminase I (BCAT1) in T-ALL, with the aim of mechanistically investigating its up-regulation and its function in the disease. During her doctoral studies, Ludovica published three original research articles in international peer-reviewed scientific journals, one as first-author. She was awarded her doctorate in 2023 upon successful defence of her thesis. Ludovica then recently moved to the Targeted Therapeutics in Cancer Research Group of Dr. Ní Chonghaile in 2023 to pursue research focusing on metabolism and epigenetic mechanisms related to multiple myeloma.
Targeted Therapeutics in Cancer 